Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

21.69 +0.45 (+2.12%)
Streaming Delayed Price Updated: 3:29 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued. ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
News headline image
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Navigating 4 Analyst Ratings For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Preview: Pacira BioSciences's Earnings ↗
 
Via Benzinga
News headline image
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
News headline image
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
From Pacira BioSciences
Via GlobeNewswire
News headline image
NASDAQ:PCRX is an undervalued gem with solid fundamentals. ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts ↗
 
Via Benzinga
News headline image
Earnings Preview: Pacira BioSciences ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
From Pacira BioSciences
Via GlobeNewswire
News headline image
Analyst Expectations for Pacira BioSciences's Future ↗
 
Via Benzinga
News headline image
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Appoints Frank D. Lee as Chief Executive Officer
From Pacira BioSciences
Via GlobeNewswire
News headline image
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents. ↗
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
News headline image
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
From Pacira BioSciences
Via GlobeNewswire
News headline image
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals. ↗
Investors should take notice ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Third Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023
From Pacira BioSciences
Via GlobeNewswire
News headline image
American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.